Further analysis demonstrated that the PD-L1 expression was increased in response to ARID1A suppression through activating the AKT pathway.57 Fukumoto et al105 concluded that, by promoting binding of RNA polymerase II and H3K4me3 to the PD-L1 promoter in ovarian cancer, ARID1A can suppress PD-L1 expression, both at physiological baseline and during inflammation with high IFN-γ. Here, ARID1A is linked to ovarian cancer.